Biomarin Pharmaceuticals (BMRN)

$54.73 +0.51 (0.94%)
Market Cap 10.51B
Revenue (ttm) 2.85B
Net Income (ttm) 426.86M
EPS (ttm) N/A
PE Ratio 18.89
Forward PE 17.52
Profit Margin 14.96%
Debt to Equity Ratio 0.00
Volume 1,975,900
Avg Vol 2,449,956
Day's Range N/A - N/A
Shares Out 192.11M
Stochastic %K 87%
Beta 0.33
Analysts Strong Sell
Price Target $90.65

Company Profile

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic pep...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 506 6700
Address:
770 Lindaro Street, San Rafael, United States
HedgeAlerts
HedgeAlerts Nov. 16 at 9:49 PM
Hedge Alert Live - Protect Your Portfolio Contract: $BMRN $52.50 Put · NOV 21, 2025 Exp Entry Price: $0.55 - $0.80 Exit Price Target: $1.12 Profit Margin: +103% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 15 at 9:52 PM
Hedge Alert Live - Protect Your Portfolio Contract: $BMRN $52.50 Put · NOV 21, 2025 Exp Entry Price: $0.55 - $0.80 Exit Price Target: $1.12 Profit Margin: +103% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 15 at 4:01 AM
💎 LiquidTheta® Live Actionable Trade Asset: $BMRN Contracts: $BMRN January 15, 2027 $55 Calls Scale in: $9.32- $11.39 Scale out: $36.23-$62.10 Profit Potential : 449% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 5:34 PM
Hedge Alert Live - Protect Your Portfolio Contract: $BMRN $55.00 Put · NOV 21, 2025 Exp Entry Price: $1.55 - $2.00 Exit Price Target: $3.36 Profit Margin: +117% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 6:55 AM
Hedge Alert Live - Protect Your Portfolio Contract: $BMRN $52.50 Put · NOV 21, 2025 Exp Entry Price: $0.55 - $2.00 Exit Price Target: $1.23 Profit Margin: +124% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 14 at 3:10 AM
💎 LiquidTheta® Live Actionable Trade Asset: $BMRN Contracts: $BMRN January 15, 2027 $55 Calls Scale in: $9.45- $11.55 Scale out: $36.75-$63.00 Profit Potential : 296% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 12 at 8:22 PM
💎 LiquidTheta® Live Actionable Trade Asset: $BMRN Contracts: $BMRN January 15, 2027 $58 Calls Scale in: $9.22- $11.28 Scale out: $35.88-$61.50 Profit Potential : 447% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
doctordinero
doctordinero Nov. 12 at 4:49 PM
$GILD Was in the 60s for about 10 years and then off it went. Patience is king. $BIIB and $BMRN next. GLTA. $SPY
1 · Reply
Iightning
Iightning Nov. 12 at 12:41 AM
1ightning® Options Trade Alert (Actionable) | Buy $BMRN Dec 19 $55 Call | Enter: $2.50 Exit: $3.70 | Profit: 48.12% ROI | https://1ightning.com
0 · Reply
tradeitbetit
tradeitbetit Nov. 11 at 11:30 PM
$BMRN first time I see this stock hold gains …..
0 · Reply
Latest News on BMRN
BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England

Nov 11, 2025, 9:00 AM EST - 5 days ago

BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England

FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria

Oct 29, 2025, 9:00 AM EDT - 18 days ago

FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria

Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings

Oct 28, 2025, 9:48 AM EDT - 19 days ago

Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings

BioMarin Pharmaceuticals - Growing Numbers, Falling Expectations

Oct 28, 2025, 6:58 AM EDT - 19 days ago

BioMarin Pharmaceuticals - Growing Numbers, Falling Expectations

BioMarin Pharmaceutical Inc. (BMRN) Q3 2025 Earnings Call Transcript

Oct 27, 2025, 8:17 PM EDT - 20 days ago

BioMarin Pharmaceutical Inc. (BMRN) Q3 2025 Earnings Call Transcript

BioMarin Pharma plans to divest struggling gene therapy

Oct 27, 2025, 6:34 PM EDT - 20 days ago

BioMarin Pharma plans to divest struggling gene therapy

BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update

Oct 27, 2025, 4:03 PM EDT - 20 days ago

BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update

BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET

Oct 22, 2025, 4:05 PM EDT - 25 days ago

BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET

BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory Risks

Sep 30, 2025, 7:01 AM EDT - 6 weeks ago

BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory Risks

BioMarin Pharmaceutical Inc. (BMRN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 4:46 PM EDT - 2 months ago

BioMarin Pharmaceutical Inc. (BMRN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment

Sep 8, 2025, 1:56 PM EDT - 2 months ago

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment

PTCT

BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting

Sep 8, 2025, 9:00 AM EDT - 2 months ago

BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting

BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism

Sep 6, 2025, 11:05 AM EDT - 2 months ago

BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism

BioMarin Pharmaceutical Inc. (BMRN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 4, 2025, 11:27 AM EDT - 2 months ago

BioMarin Pharmaceutical Inc. (BMRN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Sep 3, 2025, 3:32 PM EDT - 2 months ago

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

ARGX BBH CYTK IBB XBI

BioMarin Pharmaceutical Inc. (BMRN) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 3, 2025, 11:01 AM EDT - 2 months ago

BioMarin Pharmaceutical Inc. (BMRN) Presents At Cantor Global Healthcare Conference 2025 Transcript

BioMarin to Participate in Upcoming Investor Conferences

Aug 27, 2025, 9:00 AM EDT - 2 months ago

BioMarin to Participate in Upcoming Investor Conferences

BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401

Aug 5, 2025, 4:20 PM EDT - 3 months ago

BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401

INZY

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

Aug 5, 2025, 1:11 PM EDT - 3 months ago

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 11:04 PM EDT - 3 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Call Transcript

BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS

Aug 4, 2025, 4:02 PM EDT - 3 months ago

BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS

BioMarin Announces Appointment of Ian T. Clark to Board of Directors

Aug 1, 2025, 9:00 AM EDT - 3 months ago

BioMarin Announces Appointment of Ian T. Clark to Board of Directors

BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET

Jul 22, 2025, 9:00 AM EDT - 4 months ago

BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET

It is time for a move higher in biotech, says Mizuho's Jared Holz

Jul 7, 2025, 6:29 PM EDT - 4 months ago

It is time for a move higher in biotech, says Mizuho's Jared Holz

BBIO GILD INSM XBI

BioMarin Announces Completion of Acquisition of Inozyme

Jul 1, 2025, 8:45 AM EDT - 4 months ago

BioMarin Announces Completion of Acquisition of Inozyme

INZY

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

Jun 24, 2025, 9:00 AM EDT - 5 months ago

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

May 21, 2025, 5:56 PM EDT - 6 months ago

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

INZY

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

May 16, 2025, 7:30 AM EDT - 6 months ago

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

INZY

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

May 12, 2025, 9:05 AM EDT - 6 months ago

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:25 PM EDT - 7 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

May 1, 2025, 4:05 PM EDT - 7 months ago

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

Apr 17, 2025, 9:00 AM EDT - 7 months ago

BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET

BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion

Apr 3, 2025, 3:37 PM EDT - 8 months ago

BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion

BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria

Apr 2, 2025, 9:00 AM EDT - 8 months ago

BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria

BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

Mar 20, 2025, 9:00 AM EDT - 8 months ago

BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA

Feb 25, 2025, 9:00 AM EST - 9 months ago

BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA

BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

Feb 24, 2025, 4:05 PM EST - 9 months ago

BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors

Why Is BioMarin Stock Trading Higher On Thursday?

Feb 20, 2025, 9:39 AM EST - 9 months ago

Why Is BioMarin Stock Trading Higher On Thursday?

BioMarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 8:08 PM EST - 9 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings Call Transcript

BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

Feb 19, 2025, 4:05 PM EST - 9 months ago

BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance

BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET

Feb 5, 2025, 9:00 AM EST - 10 months ago

BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET

BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy

Jan 23, 2025, 10:42 AM EST - 10 months ago

BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

Jan 13, 2025, 12:00 PM EST - 10 months ago

BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court

BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA

Jan 6, 2025, 8:30 AM EST - 11 months ago

BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA

Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call

Nov 21, 2024, 3:00 PM EST - 1 year ago

Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024

Nov 16, 2024, 10:45 AM EST - 1 year ago

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024

BioMarin to Participate in Three Upcoming Investor Conferences

Nov 6, 2024, 8:00 AM EST - 1 year ago

BioMarin to Participate in Three Upcoming Investor Conferences

BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 8:26 PM EDT - 1 year ago

BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

Oct 29, 2024, 4:03 PM EDT - 1 year ago

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET

Oct 16, 2024, 8:30 AM EDT - 1 year ago

BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET

HedgeAlerts
HedgeAlerts Nov. 16 at 9:49 PM
Hedge Alert Live - Protect Your Portfolio Contract: $BMRN $52.50 Put · NOV 21, 2025 Exp Entry Price: $0.55 - $0.80 Exit Price Target: $1.12 Profit Margin: +103% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 15 at 9:52 PM
Hedge Alert Live - Protect Your Portfolio Contract: $BMRN $52.50 Put · NOV 21, 2025 Exp Entry Price: $0.55 - $0.80 Exit Price Target: $1.12 Profit Margin: +103% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 15 at 4:01 AM
💎 LiquidTheta® Live Actionable Trade Asset: $BMRN Contracts: $BMRN January 15, 2027 $55 Calls Scale in: $9.32- $11.39 Scale out: $36.23-$62.10 Profit Potential : 449% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 5:34 PM
Hedge Alert Live - Protect Your Portfolio Contract: $BMRN $55.00 Put · NOV 21, 2025 Exp Entry Price: $1.55 - $2.00 Exit Price Target: $3.36 Profit Margin: +117% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 6:55 AM
Hedge Alert Live - Protect Your Portfolio Contract: $BMRN $52.50 Put · NOV 21, 2025 Exp Entry Price: $0.55 - $2.00 Exit Price Target: $1.23 Profit Margin: +124% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 14 at 3:10 AM
💎 LiquidTheta® Live Actionable Trade Asset: $BMRN Contracts: $BMRN January 15, 2027 $55 Calls Scale in: $9.45- $11.55 Scale out: $36.75-$63.00 Profit Potential : 296% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 12 at 8:22 PM
💎 LiquidTheta® Live Actionable Trade Asset: $BMRN Contracts: $BMRN January 15, 2027 $58 Calls Scale in: $9.22- $11.28 Scale out: $35.88-$61.50 Profit Potential : 447% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
doctordinero
doctordinero Nov. 12 at 4:49 PM
$GILD Was in the 60s for about 10 years and then off it went. Patience is king. $BIIB and $BMRN next. GLTA. $SPY
1 · Reply
Iightning
Iightning Nov. 12 at 12:41 AM
1ightning® Options Trade Alert (Actionable) | Buy $BMRN Dec 19 $55 Call | Enter: $2.50 Exit: $3.70 | Profit: 48.12% ROI | https://1ightning.com
0 · Reply
tradeitbetit
tradeitbetit Nov. 11 at 11:30 PM
$BMRN first time I see this stock hold gains …..
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 11 at 11:12 PM
💎 LiquidTheta® Live Actionable Trade Asset: $BMRN Contracts: $BMRN January 15, 2027 $55 Calls Scale in: $8.48- $10.37 Scale out: $32.99-$56.55 Profit Potential : 134% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
DavidMacph1
DavidMacph1 Nov. 11 at 5:43 PM
$BSX Boston Scientific, $DXCM Dexcom, and $BMRN Biomarin are my top healthcare picks (listed from safest to riskiest)
1 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 11 at 2:45 AM
💎 LiquidTheta® Live Actionable Trade Asset: $BMRN Contracts: $BMRN January 15, 2027 $55 Calls Scale in: $8.08- $9.87 Scale out: $31.41-$53.85 Profit Potential : 61% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
Iightning
Iightning Nov. 10 at 9:33 PM
1ightning® Options Trade Alert (Actionable) | Buy $BMRN Nov 21 $55 Call | Enter: $0.67 Exit: $1.04 | Profit: 55.28% ROI | https://1ightning.com
0 · Reply
DairyQueen505
DairyQueen505 Nov. 10 at 8:19 PM
$BMRN up on a green market day. Weird. New low Friday. $30 PT.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 8 at 5:09 AM
💎 LiquidTheta® Live Actionable Trade Asset: $BMRN Contracts: $BMRN January 15, 2027 $52 Calls Scale in: $8.60- $10.51 Scale out: $33.43-$57.30 Profit Potential : 331% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
Iightning
Iightning Nov. 7 at 8:13 PM
1ightning® Options Trade Alert (Actionable) | Buy $BMRN Nov 21 $52 Call | Enter: $1.95 Exit: $2.39 | Profit: 22.60% ROI | https://1ightning.com
0 · Reply
DairyQueen505
DairyQueen505 Nov. 7 at 3:58 PM
$BMRN finally heading lower. Could break the $50 barrier today. $40 by EOY. $30 next year.
0 · Reply
tradeitbetit
tradeitbetit Nov. 7 at 3:25 PM
$BMRN the worse stock with the best financials I have ever seen, growing revenues, profitability almost no debt and solid long term pipeline. This price action and valuation is usually reserved for decaying almost bankrupt companies #marketsarecrazy
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 7 at 3:05 AM
💎 LiquidTheta® Live Actionable Trade Asset: $BMRN Contracts: $BMRN January 15, 2027 $52 Calls Scale in: $8.60- $10.51 Scale out: $33.43-$57.30 Profit Potential : 79% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 12:48 PM
Stifel has updated their rating for BioMarin Pharmaceutical ( $BMRN ) to Hold with a price target of 61.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 5 at 10:51 PM
💎 LiquidTheta® Options Alert Asset: $BMRN Contracts: $BMRN January 15, 2027 $55 Calls Scale in: $8.39- $10.26 Scale out: $32.64-$55.95 Profit Potential : 297% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply